Immuneering (IMRX) Gross Profit (2020 - 2022)
Historic Gross Profit for Immuneering (IMRX) over the last 3 years, with Q4 2022 value amounting to $455.0.
- Immuneering's Gross Profit rose 10273.6% to $455.0 in Q4 2022 from the same period last year, while for Sep 2023 it was $455.0, marking a year-over-year decrease of 9967.9%. This contributed to the annual value of $158830.0 for FY2022, which is 8286.42% down from last year.
- According to the latest figures from Q4 2022, Immuneering's Gross Profit is $455.0, which was up 10273.6% from $19037.0 recorded in Q3 2022.
- In the past 5 years, Immuneering's Gross Profit registered a high of $367568.0 during Q3 2020, and its lowest value of -$16630.0 during Q4 2021.
- For the 3-year period, Immuneering's Gross Profit averaged around $171718.7, with its median value being $191847.0 (2020).
- Per our database at Business Quant, Immuneering's Gross Profit crashed by 10866.84% in 2021 and then skyrocketed by 10273.6% in 2022.
- Over the past 3 years, Immuneering's Gross Profit (Quarter) stood at $191847.0 in 2020, then crashed by 108.67% to -$16630.0 in 2021, then skyrocketed by 102.74% to $455.0 in 2022.
- Its Gross Profit was $455.0 in Q4 2022, compared to $19037.0 in Q3 2022 and $46486.0 in Q2 2022.